Hypofractionated Post-Mastectomy Radiation

Bruce G. Haffty, MD
Chair, Radiation Oncology RWJMS and NJMS
Associate Vice Chancellor Cancer Programs
Rutgers Biomedical Health Sciences
Rutgers Cancer Institute of New Jersey
Issues/Outline

• Hypofractionation-What is it?
• Adoption into Whole Breast RT
• Barriers to Adoption in Mastectomy and Regional Nodal RT
• Review of Data Using Hypofractionation PMRT and Regional Nodes
• Clinical Trials Completed and Ongoing
• Opportunities for Translational Research Evaluating Normal Tissue Complications and Future Directions
What is Hypo-fractionation in Radiation Therapy

• Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given once a day or less often. **Hypofractionated** radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.

• In breast cancer the typical hypofractionated daily dose is higher (2.5-3.3 Gy compared to 2.0 Gy), the total dose is lower (40-50 Gy compared to 50-60 Gy) and the total time is less (3-4 weeks compared to 5-6 weeks)

• Ideally the hypofractionated program should deliver a biologically equivalent dose as the standard regimen with respect to both tumor control normal tissue toxicity
Hypo-fractionated Whole Breast

- Multiple randomized trials now demonstrate equivalent cosmesis and outcome in patients treated with moderately hypo-fractionated whole breast radiation (3-4 weeks) when compared to the conventional 6-7 weeks of daily RT.
- Data on randomized trials is now mature out to 10+ years.
- Majority of patients on trials were treated to whole breast alone (without regional nodal radiation) and without systemic chemotherapy.
- However, chemotherapy, regional nodal radiation and young age were included in the randomized trials.
Strong Phase III data that whole breast hypofractionation is acceptable as an alternative to standard fractionation

- For women with invasive breast cancer receiving WBI without regional nodal irradiation, the preferred dose-fractionation scheme is HF-WBI to a dose of 40 Gy in 15 fractions or 42.5 Gy in 16 fractions.
- The decision to offer HF-WBI should be independent of tumor grade, hormone receptor status, HER2 receptor status, or margin status.
- The decision to offer hypofractionation should be independent of breast cancer laterality.
- The decision to offer HF-WBI should be independent of chemotherapy received prior to radiation and trastuzumab or endocrine therapy received prior to or during radiation.
New ASTRO Guidelines

• There is no evidence indicating deleterious effects of HF-WBI compared to CF-WBI in either younger or older patients, and thus HF-WBI may be used regardless of age. However, for patients with very long life expectancy, the panel suggests that physicians engage in discussions regarding the 10-year follow-up of existing randomized trials comparing HF-WBI to CF-WBI to ensure appropriately individualized decisions.

• HF-WBI may be used as an alternative to CF-WBI in patients with DCIS.

• The decision to offer HF-WBI should be independent of breast size (including central axis separation) provided that dose-homogeneity goals, as outlined in KQ4, can be achieved.
Hypofractionation in clinical radiation therapy

• Clearly shorter course of radiation have evolved as an acceptable (preferred) standard of care for the conservatively treated breast cancer patient

• Hypofractionated regimens in other disease sites including prostate, lung and other sites are evolving as acceptable alternatives

• Why not hypofractionation post mastectomy?
Why not hypo-fractionation post-mastectomy

- Fear that treating the supraclavicular region with hypo-fractionation will cause the dreaded brachial plexopathy
- Fear that treating the reconstructed breast with hypo-fractionation will result in higher complications
- Decades of randomized time-tested data demonstrating improved outcomes with conventionally fractionated PMRT and acceptable toxicity and long term effects-why change?
- Comfort level-Most radiation oncologists just do not feel comfortable and were trained to treat broader fields and regional nodes with the more conventional 5-6 weeks of RT at 180-200 cGy per day
- However, the long held concept that shorter courses of RT with higher daily RT doses result in more fibrosis and long term complications is simply not evident from the available data in breast cancer.
The UK START Trials

START Trials: design and endpoints

Women with completely excised invasive breast cancer, T1-3 N0-1 M0

Primary endpoint:
- local-regional relapse

Secondary endpoints include:
- normal tissue effects (assessed by physicians, photographs & patients)
- disease-free & overall survival

Trial A
N=2236

50Gy in 25 # (2.0Gy) 5 wks
N=749

39.0Gy in 13 # (3.0Gy) 5 wks
N=750

41.6Gy in 13 # (3.2Gy) 5 wks
N=737

Trial B
N=2215

50Gy in 25 # (2.0Gy) 5 wks
N=1105

40Gy in 15 # (2.67Gy) 3 wks
N=1110

Recruitment from 35 UK centres 1999-2002

Median follow-up:
9.3 years (Trial A)
9.9 years (Trial B)

This presentation is the intellectual property of the author/presenter. Contact at jo.haviland@icr.ac.uk for permission to reprint and/or distribute.
COSMETIC OUTCOME: START B

San Antonio Breast Cancer Symposium – December 4-8, 2012

**Trial B:** Any moderate/marked effect in the conserved breast (physician assessments)

<table>
<thead>
<tr>
<th>Time from randomisation (years)</th>
<th>Hazard Ratio (95%CI)</th>
<th>Absolute difference at 5 years (95%CI)</th>
<th>Absolute difference at 10 years (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- 40 Gy (332/1005; 10 yr rate 37.9%, CI 34.5-41.5)
- 50 Gy (394/1001; 10 yr rate 45.3%, CI 41.7-49.0)

% of patients with no moderate/marked effect in the breast

This presentation is the intellectual property of the author/presenter. Contact at jo.haviland@jcr.ac.uk for permission to reprint and/or distribute.
Normal Tissue Effect: START B

San Antonio Breast Cancer Symposium – December 4-8, 2012

Trial B: Normal tissue effects – individual endpoints (physician assessments)

- Change in photographic breast appearance (5 yrs)
- Breast shrinkage
- Breast induration
- Breast oedema
- Telangiectasia
- Shoulder stiffness
- Arm oedema

40 Gy better vs. 50 Gy better

Hazard Ratio (95% CI)

This presentation is the intellectual property of the author/presenter. Contact jo.haviland@icr.ac.uk for permission to reprint and/or distribute.
Hypofractionation with Regional Nodal Treatment or Post Mastectomy

- Although conventional fractionation remains the acceptable standard for treating the regional lymphatics hypofractionation of the regional lymphatics has been successfully done throughout the years.
- British Columbia Pre-menopausal PMRT Randomized Trial
  - 37.5 Gy in 16 Fractions of 2.34 Gy
- START A and START B-RNI Administered to 14% of Patients
  - 42.9 Gy in 3.3 Gy Fractions x 13 over 5 weeks START A
  - 41.6 Gy in 3.2 Gy Fractions x 13 over 5 weeks START A
  - 40 Gy in 2.6 Gy Fractions x 15 over 3 weeks START B
# Pre-existing data on hypofractionated RNI

<table>
<thead>
<tr>
<th>Study</th>
<th>Time Period</th>
<th>Patients</th>
<th>RNI Dose (Gy)</th>
<th>Fractions</th>
<th>EQD2</th>
<th>Plexopathy rate</th>
<th>Median Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melbourne(^4)</td>
<td>1958-1962</td>
<td>117, PMRT</td>
<td>63</td>
<td>12</td>
<td>114.2</td>
<td>73%</td>
<td>2.5 years</td>
</tr>
<tr>
<td>Sweden(^39)</td>
<td>1963-65</td>
<td>71, PMRT</td>
<td>57</td>
<td>17</td>
<td>76.3</td>
<td>63%</td>
<td>34 years</td>
</tr>
<tr>
<td>Hamburg, Germany(^46)</td>
<td>1980-1993</td>
<td>140, SCL</td>
<td>52.0</td>
<td>20</td>
<td>59.8</td>
<td>14%</td>
<td>8 years</td>
</tr>
<tr>
<td>St. Thomas, London(^1)</td>
<td>1968-1974</td>
<td>411, PMRT</td>
<td>35</td>
<td>6</td>
<td>68.5</td>
<td>NR</td>
<td>10 years</td>
</tr>
<tr>
<td>Western General Hospital, Edinburgh(^41)</td>
<td>1979-1982</td>
<td>484, PMRT and RNI</td>
<td>42.5</td>
<td>10</td>
<td>66.4</td>
<td>1%</td>
<td>10 years</td>
</tr>
<tr>
<td></td>
<td>1982-1984</td>
<td>289, PMRT and RNI</td>
<td>42.5</td>
<td>20</td>
<td>43.8</td>
<td>1%</td>
<td></td>
</tr>
</tbody>
</table>
## Pre-existing data on hypofractionated RNI

<table>
<thead>
<tr>
<th>Study</th>
<th>Time Period</th>
<th>Patients</th>
<th>RNI Dose (Gy)</th>
<th>Fractions</th>
<th>EQD2</th>
<th>Plexopathy rate</th>
<th>Median follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Necker, Paris</td>
<td>1984-1989</td>
<td>230, RNI use uncertain</td>
<td>23</td>
<td>4</td>
<td>44.6</td>
<td>0</td>
<td>4 (min)</td>
</tr>
<tr>
<td>BC PMRT</td>
<td>1979-1986</td>
<td>318 (164 PMRT)</td>
<td>35 Gy</td>
<td>16</td>
<td>37 Gy</td>
<td>0</td>
<td>20 years</td>
</tr>
<tr>
<td>Fairchild</td>
<td>1990-1996</td>
<td>1142</td>
<td>40</td>
<td>16</td>
<td>45 Gy</td>
<td>&lt;1</td>
<td>8 years</td>
</tr>
<tr>
<td>Powell</td>
<td>1982-1984</td>
<td>1) 338 2) 111</td>
<td>1) 45 2) 54</td>
<td>1) 15 2) 30</td>
<td>1) 56 2) 51</td>
<td>6% 1%</td>
<td>5.5 years</td>
</tr>
<tr>
<td>RMH/GOC</td>
<td>1986-1998</td>
<td>290 (2/3rd hypofx)</td>
<td>42.9 Gy 39 Gy</td>
<td>13</td>
<td>47-49 Gy</td>
<td>0</td>
<td>8 years</td>
</tr>
<tr>
<td>START A/B</td>
<td>1998-2002</td>
<td>479 (278 hypofx)</td>
<td>40 Gy 42.9 Gy 39 Gy</td>
<td>13-15</td>
<td>47-49 Gy</td>
<td>1 (&lt;1)</td>
<td>9.3 years</td>
</tr>
</tbody>
</table>
## Snapshot of hypofractionation trials…

<table>
<thead>
<tr>
<th>Trial</th>
<th>Years</th>
<th>Patients (N)</th>
<th>Arms (Gy/Fractions)</th>
<th>Age &lt; 50 (%)</th>
<th>Boost (%)</th>
<th>Chemo-therapy (%)</th>
<th>Regional Node Irradiation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMH/GOC</td>
<td>1986-1998</td>
<td>1,410</td>
<td>50/25</td>
<td>42.9/13</td>
<td>30</td>
<td>75</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>39/13</td>
<td>42.5/16</td>
<td>25</td>
<td>0</td>
<td>11</td>
</tr>
<tr>
<td>OCOG</td>
<td>1993-1996</td>
<td>1,234</td>
<td>50/25</td>
<td>41.6/13</td>
<td>23</td>
<td>61</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>39/13</td>
<td>40/15</td>
<td>21</td>
<td>43</td>
<td>22</td>
</tr>
<tr>
<td>START A</td>
<td>1998-2002</td>
<td>2,236</td>
<td>50/25</td>
<td>41.6/13</td>
<td>23</td>
<td>61</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>39/13</td>
<td>40/15</td>
<td>21</td>
<td>43</td>
<td>22</td>
</tr>
</tbody>
</table>
Hypo-fractioned Radiation Equivalent Dose in 2 Gy Fractionation, Incidence of Brachial Plexopathy based on published literature.

The low end of the chart magnified...
Brachial plexopathy with hypofx:

- Exceeding known tolerance of brachial plexus will result in brachial plexopathy.
- Late neuropathy possible (but incidence plateaus at 6 yrs)
- Understanding LQ parameters and keeping EQD2 around 50 Gy is very safe
- Isoeffective schedules will behave isoeffectively on the plexus

WHAT ABOUT THE CHEST WALL/RECONSTRUCTION??
Hypofractionation on a chest wall reconstruction:

- Not definitive, modern data.

- Data of hypo-fractionation on the intact breast suggests better normal tissue effects compared to conventional fractionation.
CINJ 041001: phase II trial

• Hypothesis: A hypofractionated course of PMRT is not more toxic than a conventionally fractionated course of PMRT.

• Patients: Stage IIA-IIIC (including clinical stage prior to NAC)

• 36.63 Gy in 11 daily fractions (3.33Gy x 11)

• Chest wall plus SCL/AX +/- IMNs

• BED equivalent to 45-50 Gy for late effects and tumor control

• Optional scar boost of 4 fractions (3.33Gy), total 15 fractions. BED ~ 60Gy.
$BED = nd \left( 1 + \frac{d}{\text{=} \ln 2 (T \div (T_{pot}))} \right)$

- $d = \text{dose/fraction}$
- $n = \# \text{ of identical fractions}$.
- $T = \text{overall treatment time after initial time lag to proliferation}$
- $T_{pot} = \text{potential tumor doubling time}$.
# Comparison of Hypofractionation Schedules

## 2 Gy Equivalent Dose (Alpha/beta = 4)

<table>
<thead>
<tr>
<th>Target/Dose</th>
<th>Standard</th>
<th>CINJ</th>
<th>UK</th>
<th>Canadian</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Breast and Nodal Dose</td>
<td>2 Gy x 25 To 50.0 Gy</td>
<td>3.33 Gy x 11 To 36.63 Gy</td>
<td>2.66 x 15 To 40 Gy</td>
<td>266 x 16 To 42.56 Gy</td>
</tr>
<tr>
<td></td>
<td>50 Gy</td>
<td>44.75 Gy</td>
<td>44.4</td>
<td>47.24</td>
</tr>
<tr>
<td>Total Tumor Bed Dose with Boost</td>
<td>2 Gy x 30 To 60 Gy</td>
<td>3.33 Gy x 15 To 49.95 Gy</td>
<td>2.66 gy x 15 + 250 x 4 to 50 Gy</td>
<td>266 x 16 (42.56) + 250 x 4 to 52.56 Gy</td>
</tr>
<tr>
<td></td>
<td>60 Gy</td>
<td>61 Gy</td>
<td>55.5 Gy</td>
<td>58 Gy</td>
</tr>
</tbody>
</table>
CINJ 041001: phase II trial

- Primary Endpoint: Serious toxicity rate (chest wall pain or complications > grade 2, brachial plexopathy, pneumonitis > grade 2.)

- Sample size: Assuming background rate of toxicity at 3%, we can exclude a rate greater than 9% with 90% confidence and 80% power with 67 patients if no more than 4 serious toxicities are observed. Stopping criteria after the first 33 patients.

- Secondary endpoint: If no more than 5 LRRs in cohort of 67, the 90% CI of true LRR is between 3.7-14.5%.
Rutgers Hypo-fractionation Trial

- Prospective Phase II Trial (NCT01417286)
- 69 Patients enrolled between December 2011 and December 2014 at Rutgers CINJ and Huntsman Cancer Center at the University of Utah
- Stage II A to IIIc disease post-mastectomy with or without reconstruction (41 or 69% of patients had reconstruction)
- Treated PMRT 4995 Gy/3 Weeks (3.33 Gy/11 Fx/ to chest wall and nodes + 3.33Gy/4 Fx Boost)
- Primary Endpoint-total greater than Grade 2 Toxicity Rate below 9%
- Secondary Endpoint-Recurrence Rate between 3.7 and 14.5%
- Reconstruction Complications Attributed to Radiation -24%
Results

  - 69 patients enrolled, 67 evaluable patients.
  - Median follow-up = 2 years.
  - Three CTCAE grade 3 toxicities,
    - infected seroma requiring re-operation before RT (patient not evaluable),
    - one contralateral reconstruction infection,
    - one ipsilateral wound complication.
  - 2 loco-regional recurrences (4.5%)
  - 5 distant recurrences
  - 39 pre-RT reconstructions or temporary expanders (TE)
  - 32 patients with post-RT delayed or completed (TE) reconstructions
  - 6 patients with implant failure or removal
  - 7 patients with minor/elective revisions of reconstruction
Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial

Atif J. Khan, Matthew M. Poppe, Sharad Goyal, Kristine E. Kokeny, Thomas Kearney, Laurie Kirstein, Deborah Toppmeyer, Dirk F. Moore, Chunxia Chen, David K. Gaffney, and Bruce G. Haffty

Table 2. Treatment-Related Grade 2 Toxicities

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>No.</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>16</td>
<td>24.0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>5</td>
<td>7.5</td>
</tr>
<tr>
<td>Pain</td>
<td>3</td>
<td>4.5</td>
</tr>
<tr>
<td>Lymphedema</td>
<td>3</td>
<td>4.5</td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>1</td>
<td>1.4</td>
</tr>
<tr>
<td>Other*</td>
<td>1</td>
<td>1.4</td>
</tr>
</tbody>
</table>

*Hot flashes.

[Survival probability graph]

[Local Recurrence-Free Survival (months)]
Hypofractionation PMRT-Moving forward

- These Phase II data **suggest** that radiation therapy delivered in 3 weeks is safe and effective post mastectomy setting treating the regional lymphatics as well as the reconstructed breast
- However, Single arm Phase II date ideally should be validated by randomized Phase III studies
- These Phase II data, along with the work of multiple individuals and cooperative groups helped to move the upcoming ALLIANCE Phase III trial forward
- The trial has been activated in Alliance.
- The trial has a Number: A221505
More Importantly the trial has a name

- RT-CHARM
- Radiation
- Therapy
- Conventional or
- Hypofractionated
- After
- Reconstruction and
- Mastectomy
Protocol development team

- Matthew Poppe, MD RadOnc, PI, U. of Utah
- Atif Khan, MD RadOnc, Co-Investigator, Rutgers CINJ
- Bruce Haffty, MD RadOnc, Co-Investigator, Rutgers CINJ
- Jamie Wagner, DO, Surgical Oncology, University Kansas
- Eric Hansen, MD, Community Oncologist, Portland, OR.
- Jay Agarwal, MD Plastic Surgery, U. of Utah
- Jared Foster, PhD Statistics, Mayo Clinic
- Jane Armer, PhD, RN, Lymphedema Outcomes, U. of Missouri
- Iwa Kong, MD, MSc, Cosmesis Assessments, McMaster U.

**Intergroup Collaboration**

- Tim Whelan, BM, BCh, MSc, McMaster U., NCIC-CTG
- Douglas Arthur, MD, VCU, NRG
Trial Concept

• Non-Inferiority design
  – Ensure that hypofx PMRT has acceptable reconstruction complication compared to standard fractionation
    • Primary Endpoint - Evaluate the breast reconstruction complication rate at 2 years after completion of post mastectomy radiation (Baker 3 or 4 contracture, implant removal, unplanned hospitalization or re-operation).

• 2nd endpoint – PMRT toxicity, LC and LRC, photographic cosmetic assessment, lymphedema, PROs and cost effectiveness.
Trial Design

• 792 evaluable pts (396/arm). Target Accrual 880 Patients to allow for 10% dropout rate; Accrual estimate = 30 pts/month
• 90% power, one sided p=0.025
• Non-Inferiority Design: Hypo-fractionation is not inferior to standard fractionation with respect to the primary endpoint of reconstruction complications (Complication rate with hypofx is no greater that 10% higher than standard fx)
• Assume base reconstruction complications from PMRT 25%
  – Stats powered to exclude an increase in 10% rate of complications with hypo-fractionation or a rate of 35%
  – Baker 3 or 4 contracture, implant removal, unplanned hospitalization or re-operation
What is the background rate of reconstruction complications??

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Complications</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benediktsson et al. 2006</td>
<td>107 pts. PMRT &amp; Immediate reconstruction, saline prosthesis</td>
<td>41.7% Baker 3 or 4 contracture</td>
<td></td>
</tr>
<tr>
<td>Christante, et al. 2010</td>
<td>100 pts. PMRT &amp; Immediate breast reconstruction</td>
<td>44% complications and 31% required implant removal</td>
<td>Delayed reconstruction patients had only a 22% complication rate</td>
</tr>
<tr>
<td>Alderman, et al. 2002</td>
<td>326 pts PMRT, 12 centers</td>
<td>52% complications in immediate reconstruction</td>
<td>Delayed reconstruction rate 33%</td>
</tr>
<tr>
<td>Fowble, et al. 2015</td>
<td>99 pts Immed TE and PMRT</td>
<td>18% failure rate 3.8 yrs</td>
<td></td>
</tr>
<tr>
<td>Ho, et al. 2012</td>
<td>151 pts with implant swap and recon before RT</td>
<td>7-year PIRR 30%. 45% (n=17) Baker 3 or 4 contracture</td>
<td>17% replacement, 13% removal</td>
</tr>
</tbody>
</table>
A221505 RT CHARM

Clinical Stage II or III Breast cancer

Mastectomy with nodal evaluation/dissection +/- adjuvant chemotherapy with reconstructive surgery planned

Sub stratify: Planned implant vs. autologous reconstruction

Randomize

**ARM 1:** Conventional PMRT.
50Gy/2Gy Chest wall /
Reconstructed Breast with
50Gy/2Gy to Regional Nodes*

**ARM 2:** Hypofractionated PMRT.
42.56Gy/2.66Gy to Chest Wall /
Reconstructed Breast and
42.56Gy/2.66Gy Regional Nodes*

*Regional Nodes will include the undissected axilla, supraclavicular fossa and internal mammary nodal chain.
Enrollment to Date

- Accrual Target-880
- Sites Approved-737
- Accrual to Date-400+
Hypo-fractionation Randomized Data

- The ALLIANCE trial is not the first randomized trial of hypo-fractionation in the post-mastectomy setting.
- A recent randomized trial from China of conventional vs hypo-fractionated radiation was reported at ASTRO 2017.
- All patients were treated with mastectomy, systemic therapy and randomized to conventional vs. hypo-fractionated post-mastectomy radiation to the chest wall and regional lymphatics.
- However, all patients in the Chinese trial were surgically treated WITHOUT RECONSTRUCTION.
Randomized Trial-Hypofractionation (43.5 gy/15Fx/3wks) vs. Standard Fractionation (50 Gy/25Fx/5Wks) Post-Mastectomy: Reported at ASTRO 2017 (Sun, Wang, et al.)

Method

A randomized phase III non-inferior trial comparing HFRT and CFR1 (Noninferiority margin: 5% difference in 5-yr LRR rate)

Target sample = 820 (June 2008 - June 2016)

Stage III breast cancer patients after mastectomy

\[ \begin{align*}
\text{CFRT} & \quad \text{2Gy*25f, 5wks (n=414)} \\
\text{HFRT} & \quad \text{2.9Gy*15f, 3wks (n=404)} \\
\end{align*} \]
Randomized Trial-Hypofractionation vs. Standard Fractionation Post-Mastectomy: Reported at ASTRO 2017 (Sun, Wang, et al.)

- LRR Primary Endpoint Median FU 52 Months
- No Difference in LRR (8.4% vs. 6.0%), DM (21.3% vs. 24.3%), DFS (75.1% vs. 74.6%) or OS (84.9% vs. 87.1%) at 5 Years
- No Difference in lymphedema, shoulder disorder, pneumonitis between arms
- Fewer G3 skin reactions in hypofractionation
- No Brachial Plexopathy
### Results – Locoregional Recurrence

**Treatment Assignment**
- CFRT
- HFRT

**5-year Actuarial Rates (95% CI)**
- **CFRT**: 8.1% (5.5, 11.8)
- **HFRT**: 8.3% (5.8, 11.8)
- **Difference**: 0.2% (-4.1, 4.5)
- **HR**: 1.10 (0.67, 1.83)

**Median follow up time**: 53 months (5-111)

<table>
<thead>
<tr>
<th>Time (Years)</th>
<th>CFRT</th>
<th>HFRT</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>408</td>
<td>401</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>396</td>
<td>390</td>
<td>6</td>
</tr>
<tr>
<td>2</td>
<td>342</td>
<td>331</td>
<td>-11</td>
</tr>
<tr>
<td>3</td>
<td>286</td>
<td>276</td>
<td>-10</td>
</tr>
<tr>
<td>4</td>
<td>215</td>
<td>222</td>
<td>-7</td>
</tr>
<tr>
<td>5</td>
<td>162</td>
<td>154</td>
<td>-8</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cumulative number of events</th>
<th>CFRT</th>
<th>HFRT</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>1</td>
<td>15</td>
<td>20</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>26</td>
</tr>
<tr>
<td>3</td>
<td>23</td>
<td>28</td>
</tr>
<tr>
<td>4</td>
<td>26</td>
<td>29</td>
</tr>
</tbody>
</table>
Results – Overall Survival

5-year OS Rates (95% CI)
- CFRT: 85.6% (80.9, 89.2)
- HFRT: 83.2% (78.3, 87.1)
- HR: 1.13 (0.78, 1.62)
Future Directions/Translational Research

• While it is likely that hypofractionation as well as conventional fractionation will be acceptable in the vast majority of patients there clearly are some patients where toxicity, particularly longer term fibrosis and complications from radiation are more significant

• Identification of patients at higher risk of complications/fibrosis and increased reactions to radiation is an opportunity ripe for future investigation

• While still in its infancy there are a number of previous and ongoing studies evaluating single nucleotide polymorphisms to predict for increased risk of radiation complications
Polymorphisms and the Risk of Radiation Toxicity

- There are a number of genes typically associated with DNA repair processes, where variants are common in breast cancer patients. Candidates include BRCA1/2, ATM, TGF-B, CHEK2, ERCC1, PALB2, TNF-a, and others.
- Thus far, for the most part data are hypothesis generating without any clear contraindications or strong associations of adverse outcomes in patients with genetic mutations with the notable exceptions of:
  - ATM Homozygotes-Rare condition where ATM homozygotes are at increased risk of significant acute radiation toxicity
  - P53-Li-Fraumeni-where patients with this rare condition
Table. Multivariable Logistic Regression to Determine Grades 2 to 3 Fibrosis Among 205 Patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Level</th>
<th>OR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>C−509T genotype</td>
<td>C/C</td>
<td>1 [Reference]</td>
<td>.02</td>
</tr>
<tr>
<td></td>
<td>C/T or T/T</td>
<td>4.47 (1.25-15.99)</td>
<td></td>
</tr>
<tr>
<td>Randomization arm</td>
<td>CF WBI</td>
<td>1 [Reference]</td>
<td>.97</td>
</tr>
<tr>
<td></td>
<td>HF WBI</td>
<td>1.02 (0.38-2.77)</td>
<td></td>
</tr>
<tr>
<td>Panel physician-assessed</td>
<td>1-2</td>
<td>1 [Reference]</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>cosmesis</td>
<td>(Excellent-good)</td>
<td>7.09 (2.41-20.90)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3-4</td>
<td>(Fair-poor)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CF, conventionally fractionated; HF, hypofractionated; OR, odds ratio; WBI, whole-breast irradiation.

Table Title:
Multivariable Logistic Regression to Determine Grades 2 to 3 Fibrosis Among 205 Patients
Single Nucleotide Polymorphism rs1801516 in Ataxia Telangiectasia-Mutated Gene Predicts Late Fibrosis in Cancer Patients After Radiotherapy

A PRISMA-Compliant Systematic Review and Meta-Analysis

Yuyu Zhang, MD, Ziling Liu, MD, Mengmeng Wang, MD, Huimin Tian, MD, Keju Su, MD, Jiuwei Cui, MD, Lihua Dong, MD, and Fujun Han, MD

**Figure 2.** Forest plot for the association between the ataxia telangiectasia-mutated polymorphism rs1801516 and the risk of late fibrosis. CI = confidence interval, OR = odds ratio.
Current Ongoing Studies at Rutgers

• Prospectively collected blood samples on nearly 5000 breast cancer patients for analysis of single nucleotide polymorphisms

• Currently attempting to identify population of nearly 1000 treated with BCS+RT, where we will look at correlation of specific polymorphisms with outcomes including fibrosis, cosmesis and local-regional relapse.
Conclusions

- Moderate Hypo-fractionation (3-4 week courses of radiation) following mastectomy is likely highly effective and safe based on historical available clinically reliable data.
- However, the bulk of data treating regional lymphatics accumulated to date has been with standard 5-6 week radiation schedules.
- Fear of brachial plexopathy is a deterrent to hypo-fractionation of the regional lymphatics and supraclavicular fossa.
- Fear of increased fibrosis with “more aggressive” fractionation schemes in reconstructed patients is a deterrent to hypo-fractionation in the post-mastectomy reconstructed patient.
- However, available data suggest that moderate hypo-fractionation (2.6-3.3 Gy over 3-4 weeks) does not result in excess fibrosis or brachial plexopathy.
Conclusion/Take Home Messages

• The current Alliance A221505 (RT_CHARM) randomized trial will address the issue of moderate hypo-fractionation in the setting of mastectomy and reconstruction.

• The randomized Chinese trial (Sun, Wang et al.) and other data lend further support to the long term safety and efficacy of moderate hypo-fractionation in the post mastectomy setting.

• Together these data support the potential for moderate hypofractionation in the post-mastectomy setting where radiation could be delivered in 3-4 weeks to the chest wall with or without reconstruction and the regional lymphatics.

• ENROLL in A221505 RT-CHARM

• Analysis of Genetic Variations in Specific Genes May help to identify those patients at higher risk of complications from RT.
THANK YOU!

Bruce G. Haffty, MD